Business
We market these products to all branches of the U.S. military and to foreign defense organizations that we are permitted to sell our products to, as well as to U.S. and to international prime defense contractors.
ULTRALIFE CORP: Revenue grew 16.2% to $191M from $164M. Net income turned into a $5.898M loss from $6.312M of profit. Free cash flow declined 51.6% to $7.118M from $14.7M. Operating margin contracted 915 bps to -3.09%. ULTRALIFE CORP's annual comparison also shows free cash flow declined despite revenue growth; stock compensation grew faster than revenue; capital spending grew faster than revenue.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 16.2% to $191M from $164MOK
- Profitability — Net income turned into a $5.898M loss from $6.312M of profitWatch
- Cash flow — Free cash flow declined 51.6% to $7.118M from $14.7MWatch
- Margins — Operating margin contracted 915 bps to -3.09%Watch
- Accounting — Controls ineffective; staffing and IT weaknessesWatch
- Insiders — 18 purchases and 0 salesOK
Where the revenue comes from
Fiscal 2025, as ULTRALIFE CORP reports it. History and quarterly detail are in the app.
- Battery & Energy Products$178.0M
- Communications Systems$13.1M
Latest filings
- 10-Q · Quarterly report2026-08-07
- 8-K · Company announcement2026-08-07
- 8-K · Company announcement2026-07-23
- DEF 14A · Annual proxy (pay & governance)2026-06-02
- 10-Q · Quarterly report2026-05-08
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ULTRALIFE CORP, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.